SynthesisMissouri medicine
Adverse Childhood Experiences and Antidepressant Therapy: A Systematic Review.
Synthesis in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Adverse Childhood Experiences in the Development of Major Depressive Disorder and Treatment-Resistant Depression.Child psychiatry and human development · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse childhood experiences (ACEs) increase depression risk and may affect antidepressant (ADM) treatment outcomes; however, cumulative research on each ACE in conjunction with ADM outcomes is lacking. This review aims to examine the relationship between ACEs and ADM. We examined PsychInfo and PubMed/MEDLINE databases from 2010-2025 and identified 26 publications that met review criteria (i.e., peer-reviewed and concurrently examined ACEs and ADM). ACEs were associated with an increased propensity to use ADMs, an interaction between DNA methylation and ADM efficacy, an increased risk of suicide while on ADMs, and ADM responsiveness. The majority of the studies show serotonin modulators and stimulators, selective serotonin reuptake inhibitors, and serotonin norepinephrine reuptake inhibitors are associated with fewer depressive symptoms in ACE survivors. Multiple ACEs and child abuse impaired ADM effectiveness. Yet, genetic links and age when the ACE occurred may explain this vulnerability. These findings should be interpreted with caution, as cumulatively, the research often had smaller sample sizes in the ACE history groups, research often did not test antidepressants against each other, and reported depression symptom changes in the studies may be organic symptom reduction unrelated to treatment. Before medical providers initiate depression treatment, they should ask their patients about ACE history. If patients confide they have these experiences, medical providers will want to consider treatment drug class and establish a plan to monitor the patient carefully for unremitting symptoms, symptoms severity, and suicide risk.
Indexed as
Identifiers
41132462PMC12543355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.